Recurrent High-Grade Glioma — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Recurrence of high-grade gliomas, including glioblastoma multiforme (grade IV) and anaplastic astrocytoma (grade III), poses an unavoidable challenge. Despite aggressive surgical resection of the primary tumor and subsequent adjuvant re-chemoradiation, patients face a dismal prognosis, with a median survival of only 11 months. Typically, recurrence manifests during MRI examinations, revealing tumor enlargement accompanied by increased edema and a noticeable mass effect. Currently, there is no established standard of treatment for managing recurrent high-grade gliomas. Options such as re-resection, re-irradiation, and chemotherapy are available, but their long-term efficacy remains unproven. Glioblastoma recurrence typically occurs approximately 32–36 weeks after initial multimodal treatment, often due to ongoing neoplastic growth within 2–3 cm of the original lesion.
Thelansis’s “Recurrent High-Grade Glioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent High-Grade Glioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Recurrent High-Grade Glioma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Recurrent High-Grade Glioma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
